Home Carboxes 85650-56-2
85650-56-2,MFCD00900588
Catalog No.:AA0036B1

85650-56-2 | 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, trans-, (Z)-2-butenedioate (1:1)

Pack Size
Purity
Availability
Price(USD)
Quantity
  
5mg
99%(HPLC)powder
in stock  
$43.00   $30.00
- +
25mg
99%(HPLC)powder
in stock  
$124.00   $87.00
- +
100mg
99%(HPLC)powder
in stock  
$369.00   $258.00
- +
1g
99
in stock  
$1,327.00   $929.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA0036B1
Chemical Name:
1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, trans-, (Z)-2-butenedioate (1:1)
CAS Number:
85650-56-2
Molecular Formula:
C21H20ClNO5
Molecular Weight:
401.8402
MDL Number:
MFCD00900588
SMILES:
Clc1ccc2c(c1)[C@H]1CN(C[C@@H]1c1c(O2)cccc1)C.OC(=O)/C=C\C(=O)O
Properties
Properties
 
BP:
357.9°C at 760 mmHg  
Form:
Solid  
MP:
141 - 143°C  
Storage:
Inert atmosphere;2-8℃;  

Computed Properties
 
Complexity:
482  
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
2  
Defined Bond Stereocenter Count:
1  
Heavy Atom Count:
28  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
2  
Rotatable Bond Count:
2  

Literature

Title: Newer antipsychotics and upcoming molecules for schizophrenia.

Journal: European journal of clinical pharmacology 20130801

Title: Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice.

Journal: Expert opinion on pharmacotherapy 20130301

Title: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.

Journal: Expert review of clinical pharmacology 20130101

Title: Development and validation of automated SPE-HPLC-MS/MS methods for the quantification of asenapine, a new antipsychotic agent, and its two major metabolites in human urine.

Journal: Biomedical chromatography : BMC 20121201

Title: Iloperidone, asenapine and lurasidone: a primer on their current status.

Journal: Expert opinion on pharmacotherapy 20120901

Title: Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

Journal: CNS drugs 20120901

Title: Involvement of 5-HT2A receptor and α2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow.

Journal: Synapse (New York, N.Y.) 20120701

Title: Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.

Journal: Pharmacopsychiatry 20120701

Title: ▼Asenapine for bipolar I disorder?

Journal: Drug and therapeutics bulletin 20120601

Title: [Asenapine in bipolar disorder: efficacy, safety and place in clinical practice].

Journal: L'Encephale 20120601

Title: Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations.

Journal: Journal of clinical pharmacology 20120501

Title: Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis.

Journal: International journal of geriatric psychiatry 20120501

Title: Asenapine: a clinical review of a second-generation antipsychotic.

Journal: Clinical therapeutics 20120501

Title: Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration.

Journal: Neuropharmacology 20120301

Title: [Antipsychotic medications for bipolar I disorders. New atypical neuroleptic drug asenapine approved].

Journal: Der Nervenarzt 20120301

Title: Quantification of asenapine and three metabolites in human plasma using liquid chromatography-tandem mass spectrometry with automated solid-phase extraction: application to a phase I clinical trial with asenapine in healthy male subjects.

Journal: Biomedical chromatography : BMC 20120201

Title: Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.

Journal: Journal of clinical psychopharmacology 20120201

Title: Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.

Journal: Journal of clinical psychopharmacology 20120201

Title: Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia.

Journal: Clinical schizophrenia & related psychoses 20120101

Title: Asenapine: a review of acute and extension phase data in bipolar disorder.

Journal: CNS neuroscience & therapeutics 20111201

Title: System for disclosing hospitality should be transparent.

Journal: BMJ (Clinical research ed.) 20111115

Title: Attenuation of chronic mild stress-induced 'anhedonia' by asenapine is not associated with a 'hedonic' profile in intracranial self-stimulation.

Journal: Journal of psychopharmacology (Oxford, England) 20111001

Title: Biological perspectives: update on newer antipsychotic drugs: are they evidence based?

Journal: Perspectives in psychiatric care 20111001

Title: Asenapine: a new antipsychotic option.

Journal: Journal of pharmacy practice 20111001

Title: Suicidal ideation associated with asenapine use: a report of 2 cases.

Journal: Journal of clinical psychopharmacology 20110801

Title: Asenapine pharmacokinetics in hepatic and renal impairment.

Journal: Clinical pharmacokinetics 20110701

Title: Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?

Journal: Expert review of neurotherapeutics 20110701

Title: Asenapine for the treatment of stuttering: an analysis of three cases.

Journal: The American journal of psychiatry 20110601

Title: Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism.

Journal: Psychopharmacology 20110401

Title: Metabolism and excretion of asenapine in healthy male subjects.

Journal: Drug metabolism and disposition: the biological fate of chemicals 20110401

Title: Update on newer antipsychotic drugs.

Journal: Journal of psychosocial nursing and mental health services 20110401

Title: Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.

Journal: The AAPS journal 20110301

Title: Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.

Journal: CNS drugs 20110301

Title: A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment.

Journal: The Journal of clinical psychiatry 20110301

Title: Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.

Journal: Postgraduate medicine 20110301

Title: Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine.

Journal: Clinical pharmacology and therapeutics 20110101

Title: Atypical antipsychotics: the two new arrivals.

Journal: Issues in mental health nursing 20110101

Title: Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials.

Journal: BMC psychiatry 20110101

Title: Asenapine: a clinical overview.

Journal: The Journal of clinical psychiatry 20110101

Title: Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat.

Journal: Behavioural brain research 20101225

Title: Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.

Journal: Journal of affective disorders 20101101

Title: Effects of asenapine on prefrontal N-methyl-D-aspartate receptor-mediated transmission: involvement of dopamine D1 receptors.

Journal: Synapse (New York, N.Y.) 20101101

Title: New antipsychotic drugs: how do their receptor-binding profiles compare?

Journal: The Journal of clinical psychiatry 20100901

Title: Evaluation of the clinical efficacy of asenapine in schizophrenia.

Journal: Expert opinion on pharmacotherapy 20100801

Title: Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects.

Journal: Biopharmaceutics & drug disposition 20100701

Title: Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder.

Journal: Pharmacopsychiatry 20100601

Title: Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder.

Journal: Expert review of neurotherapeutics 20100501

Title: Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors.

Journal: The international journal of neuropsychopharmacology 20100401

Title: Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.

Journal: Journal of affective disorders 20100401

Title: Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.

Journal: Journal of clinical psychopharmacology 20100401

Title: Asenapine induces differential regional effects on serotonin receptor subtypes.

Journal: Journal of psychopharmacology (Oxford, England) 20100301

Title: New drug information. Saphris.

Journal: JAAPA : official journal of the American Academy of Physician Assistants 20100301

Title: Asenapine (Saphris) sublingual tablets for schizophrenia and bipolar disorder.

Journal: The Medical letter on drugs and therapeutics 20100208

Title: New drugs: asenapine, iloperidone, and bepotastine besilate.

Journal: Journal of the American Pharmacists Association : JAPhA 20100101

Title: Asenapine versus olanzapine in acute mania: a double-blind extension study.

Journal: Bipolar disorders 20091201

Title: Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.

Journal: International journal of clinical practice 20091201

Title: Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania.

Journal: Drugs of today (Barcelona, Spain : 1998) 20091201

Title: Asenapine effects in animal models of psychosis and cognitive function.

Journal: Psychopharmacology 20091101

Title: A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.

Journal: Bipolar disorders 20091101

Title: Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation.

Journal: Journal of clinical pharmacology 20091101

Title: Asenapine.

Journal: Nature reviews. Drug discovery 20091101

Title: Asenapine approved for treatment of schizophrenia, bipolar disorder.

Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090915

Title: Asenapine.

Journal: CNS drugs 20090901

Title: Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia.

Journal: Clinical pharmacology and therapeutics 20090701

Title: Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms.

Journal: Psychopharmacology 20090601

Title: Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain.

Journal: Synapse (New York, N.Y.) 20090501

Title: Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20090301

Title: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.

Journal: Journal of psychopharmacology (Oxford, England) 20090101

Title: Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions.

Journal: Psychopharmacology 20090101

Title: Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.

Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20081101

Title: Differential regional and dose-related effects of asenapine on dopamine receptor subtypes.

Journal: Psychopharmacology 20080501

Title: Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.

Journal: Psychopharmacology 20080201

Title: Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.

Journal: The Journal of clinical psychiatry 20071001

Title: Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale.

Journal: Psychopharmacology bulletin 20070101

Title: Actions of ORG 5222 as a novel psychotropic agent.

Journal: Pharmacology, biochemistry, and behavior 19900301

Title: Stoner SC, et al. Asenapine: a clinical review of a second-generation antipsychotic. Clin Ther. 2012 May;34(5):1023-40.

Title: Shahid M, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73.

Title: Ohyama M,et al. Asenapine reduces anxiety-related behaviours in rat conditioned fear stress model. Acta Neuropsychiatr. 2016 Dec;28(6):327-336.

Title: Ene HM, et al. Effects of repeated asenapine in a battery of tests for anxiety-like behaviours in mice. Acta Neuropsychiatr. 2016 Apr;28(2):85-91.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:85650-56-2 Molecular Formula|85650-56-2 MDL|85650-56-2 SMILES|85650-56-2 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, trans-, (Z)-2-butenedioate (1:1)